AstraZeneca has turned to Novoheart’s “human heart-in-a-jar” technology to create a preclinical model that mimics a form of heart failure for which there is no effective therapy available.
Based on Novoheart’s human ventricular cardiac organoid chamber (hvCOC) technology, the companies are aiming to develop a new in vitro model that can reproduce the characteristics of heart failure with preserved ejection fraction (HFpEF). In this condition—which occurs in 40 to 60 percent of patients with heart failure—the heart pumps normally, but is too stiff to fill properly.
“Novoheart brings expertise in tissue-engineered cardiac models derived from healthy and patient induced… Read more »
UNDERWRITERS AND PARTNERS
